Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis

Donna E. Reece, MD, Madeline Phillips, BAS, Beryl Chung, Christine I. Chen, MD, Esther Masih-Khan, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Suzanne Trudel, MD, Victor H Jimenez-Zepeda, MD, PD, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 3231.

https://doi.org/10.1182/blood.V122.21.3231.3231

Published: 2013

Journal Articles

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

Sophia Farooki, MD, FRCPC, Manjula Maganti, Donna E Reece, MD, FRCPC, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5315.

https://doi.org/10.1182/blood.V122.21.5315.5315

Published: 2013

Journal Articles

Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL)

Donna E. Reece, MD, Madeline Phillips, BAS, Christine I. Chen, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Suzanne Trudel, MD, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5378.

https://doi.org/10.1182/blood.V122.21.5378.5378

Published: 2013

Journal Articles

Botezomib Containing Regimens Provide a Rapid Hematological and Cardiac Response in Patients with AL Amyloidosis

Victor H Jimenez-Zepeda, MD, PD, Donna Reece, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD, PhD, FRACP, FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 4064.

https://doi.org/10.1182/blood.V120.21.4064.4064

Published: 2012

Journal Articles

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Danielle C Croucher, Victor H Jimenez-Zepeda, MD, PD, Zhi Hua Li, Ellen Wei, Brent DG Page, James Turkson, Patrick T Gunning, Suzanne Trudel, MD, MSC, FRCPC

Blood (2011) 118 (21): 5101.

https://doi.org/10.1182/blood.V118.21.5101.5101

Published: 2011

Journal Articles

Very Good Partial Response and Complete Response Predict Superior Overall Survival and Progression Free Survival After Single Autologous Stem Cell Transplant in Patients with Multiple Myeloma,

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Andrew Winter, Sr., RN, Norman Franke, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4111.

https://doi.org/10.1182/blood.V118.21.4111.4111

Published: 2011

Journal Articles

Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Norman Franke, MD, Andrew Winter, Sr., RN, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4121.

https://doi.org/10.1182/blood.V118.21.4121.4121

Published: 2011

Journal Articles

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, MSC, FRCPC, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 2936.

https://doi.org/10.1182/blood.V118.21.2936.2936

Published: 2011

Journal Articles

The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis

Joseph R. Mikhael, MD, Steven R. Schuster, MD, Victor H Jimenez-Zepeda, MD, PD, Nancy Bello, Jacy Spong, Craig B. Reeder, MD, A. Keith Stewart, MD, P.Leif Bergsagel, MD, Rafael Fonseca

Blood (2010) 116 (21): 3063.

https://doi.org/10.1182/blood.V116.21.3063.3063

Published: 2010

Journal Articles

Light Chain Deposition Disease: Impact of Stem Cell Tranplant on Hematological Response Achievement.

Victor H Jimenez-Zepeda, MD, PD, Norman Franke, MD, Andrew Winter, Donna E. Reece, MD, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Ahmed M. Rabea, MD, Vishal Kukreti, MD, FRCPC

Blood (2010) 116 (21): 4600.

https://doi.org/10.1182/blood.V116.21.4600.4600

Published: 2010

Journal Articles

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Ahmed M. Rabea, MD, Vishal Kukreti, MD, FRCPC

Blood (2010) 116 (21): 5028.

https://doi.org/10.1182/blood.V116.21.5028.5028

Published: 2010

Journal Articles

Studies of BP-1-102, a Novel Direct Small-Molecule Inhibitor of Stat3 Demonstrates Substantial Anti-Myeloma Pre-Clinical Activity

Victor H Jimenez-Zepeda, MD, PD, Zhi Hua Li, Brent DG Page, Seda Zeng, Ellen Wei, Chungyee Leung-Hagesteijn, James Turkson, Patrick T. Gunning, Suzanne Trudel, MD, MSC, FRCPC

Blood (2010) 116 (21): 138.

https://doi.org/10.1182/blood.V116.21.138.138

Published: 2010

Journal Articles

Cyclophosphamide and Prednisone Induction Effectively Decreased the Incidence of Engraftment Syndrome In Patients with POEMS Syndrome Who Undergo Stem Cell Transplantation.

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Ahmed M. Rabea, MD, Vishal Kukreti, MD, FRCPC

Blood (2010) 116 (21): 1318.

https://doi.org/10.1182/blood.V116.21.1318.1318

Published: 2010

Journal Articles

High-Dose Melphalan for AL Amyloidosis: The Importance of Case Selection to Improve Clinical Outcomes

Victor H Jimenez-Zepeda, MD, PD, Norman Franke, MD, Diego Delgado, Andrew Winter, Keith Stewart, MBA, MB, CHB, Joseph R. Mikhael, MD, Donna E. Reece, MD, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Vishal Kukreti, MD, FRCPC

Blood (2010) 116 (21): 2403.

https://doi.org/10.1182/blood.V116.21.2403.2403

Published: 2010

NARROW

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL)

Botezomib Containing Regimens Provide a Rapid Hematological and Cardiac Response in Patients with AL Amyloidosis

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Very Good Partial Response and Complete Response Predict Superior Overall Survival and Progression Free Survival After Single Autologous Stem Cell Transplant in Patients with Multiple Myeloma,

Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma

The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis

Light Chain Deposition Disease: Impact of Stem Cell Tranplant on Hematological Response Achievement.

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Studies of BP-1-102, a Novel Direct Small-Molecule Inhibitor of Stat3 Demonstrates Substantial Anti-Myeloma Pre-Clinical Activity

Cyclophosphamide and Prednisone Induction Effectively Decreased the Incidence of Engraftment Syndrome In Patients with POEMS Syndrome Who Undergo Stem Cell Transplantation.

High-Dose Melphalan for AL Amyloidosis: The Importance of Case Selection to Improve Clinical Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only